Polifarmacia en México: un reto para la calidad en la prescripción

3Citations
Citations of this article
122Readers
Mendeley users who have this article in their library.

Abstract

Objective. To analyze the prevalence of polypharmacy, as well as the factors that identify the groups with higher risk, in population study in Mexico. Materials and Methods. Descriptive analysis of the Encuesta Nacional de Salud y Nutrición 2018-19 (Ensanut 2018-19), Utilization of services (medicine section) and Household questionnaires, to obtain prevalence of polypharmacy (simultaneous consumption ≥5 medicines). A logistic regression model was used to estimate the association of polypharmacy with sociodemographic and health care factors. Results. Prevalence of polypharmacy: 18 years, 15.5%, and 65 years, 26.5%. Higher prevalence in: nephropathies (61.5%), heart disease (42.2%), chronic obstructive pulmonary disease (38.5%), diabetes (29.3%) and hypertension (26.4%). Increased possibility in adults 65 years (OR:1.95), low schooling (OR:1.54), social security (OR:1.64), serviced in public services (OR:1.7) and chronic illness (OR:1.84). Conclusions. Polypharmacy is associated with chronic disease and some sociodemographic factors. Large area of opportunity to improve quality of care, particularly pharmacological prescription to identified population with higher risk.

Cite

CITATION STYLE

APA

Poblano-Verástegui, O., Bautista-Morales, A. C., Acosta-Ruíz, O., Gómez-Cortez, P. M., & Saturno-Hernández, P. J. (2020). Polifarmacia en México: un reto para la calidad en la prescripción. Salud Publica de Mexico, 62(6), 859–867. https://doi.org/10.21149/11919

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free